Month: August 2024

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD) Half-year net sales of USD 5.0 billion, up 7% in constant currencies (up 6% in USD) Half-year core EBITDA margin[2] of 17.5%, a strong 210 basis point improvement versus H2 2023, driven by favorable biosimilars mix; within H1, margin expanded quarter-over-quarter Half-year 2024 EBITDA margin of 11.4%, due to one-time separation and transformation costs, and rationalization of specific manufacturing sites Net sales growth guidance increased to mid- to high-single digit in constant currencies (from mid-single digit) and reinforced confidence in core EBITDA margin of around...

August 8, 2024 Highlights2024 Directional1 EBITDA guidance increased from around US$1.2 billion to around US$1.3 billion 2024 Directional revenue guidance increased from around US$3.5 billion to above US$3.8 billion US$3.4 billion net increase of pro-forma Directional backlog to record-level US$33.7 billion EUR65 million (US$71 million equiv.2) additional share repurchase Existing share repurchase program of EUR65 million on track, c. 58% completed3 Award of 20-year lease & operate contract for an FSO to support the Trion field development in Mexico Rationalization of business in Angola to focus on Lease and Operate Ninth Fast4Ward® Multi-Purpose Floater (“MPF”) hull ordered           The Half Year 2024 Earnings and Interim Financial Statements are published on the Company’s website here. Øivind Tangen, CEO of SBM Offshore,...

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantSarclisa (isatuximab) in combination with standard-of-care lenalidomide, bortezomib, and dexamethasone (RVd) during 18-week induction treatment followed by transplant resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy, regardless of maintenance therapy assignment, in the investigational use for transplant-eligible newly diagnosed multiple myeloma (NDMM) GMMG-HD7 is one of six phase 3 studies to report positive results for Sarclisa in multiple myeloma (MM), which includes four positive readouts of a Sarclisa-based quadruplet in the frontline setting Results reinforce the potential of Sarclisa...

The contract will help replenish inventory of bulk vaccine required for future manufacturing and supply of freeze-dried vaccines.COPENHAGEN, Denmark, August 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has received a new order valued at USD 156.8 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to manufacture additional bulk product for JYNNEOS®, the company’s smallpox/mpox vaccine. The bulk product, representing USD 139.7 million of the contract value, will be manufactured and invoiced in 2024 and will partly replenish the inventory used to manufacture vaccines in response to the mpox outbreak in 2022. Replenishment of the bulk inventory is necessary to fulfil...

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $250,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on August 13, 2024, subject to customary closing conditions. ANI also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional...

CALGARY, Alberta, Aug. 07, 2024 (GLOBE NEWSWIRE) — Wilmington Capital Management Inc. (TSX: WCM.A, WCM.B) (“Wilmington” or the “Corporation”) today announces the positive outcome of the Wilmington shareholders (‘Shareholders”) vote at this morning’s special meeting of the Shareholders (the “Special Meeting”) held in-person, approving the previously announced transaction resolution. 8,341,129 Class A Shares, representing approximately 72.54% of the Corporation’s 11,498,181 issued and outstanding Class A shares, and 787,302 Class B Shares, representing approximately 78.92% of the Corporation’s 997,652 issued and outstanding Class B Shares, voted and 100% of the votes cast at the Special Meeting by Shareholders present or represented by proxy were cast in favour of the transaction resolution. Details of votes on all matters of business...